{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:13Z","timestamp":1792602913384,"version":"4.5.0"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41573-024-00933-4","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T06:02:27Z","timestamp":1715752947000},"page":"461-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Combating antimicrobial resistance in malaria, HIV and tuberculosis"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4319-0647","authenticated-orcid":false,"given":"Ma\u00eblle","family":"Duffey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-2643","authenticated-orcid":false,"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliano","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-6068","authenticated-orcid":false,"given":"Jeremy N.","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Fotouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-7548","authenticated-orcid":false,"given":"Mark","family":"Cockett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-3204","authenticated-orcid":false,"given":"Didier","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"933_CR1","unstructured":"ECDC, EFSA, EMA & OECD. Antimicrobial resistance in the EU\/EEA\u2014a One Health response. European Centre for Disease Prevention and Control https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-one-health-response (2022)."},{"key":"933_CR2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrd.2016.160","volume":"15","author":"J O\u2019Neill","year":"2016","unstructured":"O\u2019Neill, J. An audience with Jim O\u2019Neill. Nat. Rev. Drug. Discov. 15, 526 (2016).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"933_CR3","unstructured":"World Health Organization. World Malaria Report 2021 (WHO, 2021)."},{"key":"933_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eng.2018.11.011","volume":"5","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Artemisinin, the magic drug discovered from traditional Chinese medicine. Engineering 5, 32\u201339 (2019).","journal-title":"Engineering"},{"key":"933_CR5","unstructured":"World Health Organization. The Mekong Malaria Elimination Programme: Countries of the Greater Mekong are Stepping Up to End Malaria Bulletin 7 (WHO, 2018)."},{"key":"933_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.medj.2021.11.005","volume":"2","author":"DA Fidock","year":"2021","unstructured":"Fidock, D. A. & Rosenthal, P. J. Artemisinin resistance in Africa: how urgent is the threat? Med 2, 1287\u20131288 (2021).","journal-title":"Med"},{"key":"933_CR7","unstructured":"World Health Organization. WHO Consolidated Guidelines On Tuberculosis (WHO, 2022)."},{"key":"933_CR8","unstructured":"World Health Organization. Global Tuberculosis Report 2022 (WHO, 2022)."},{"key":"933_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie, F. et al. Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med. 387, 810\u2013823 (2022). This study, enrolling participants with XDR TB, shows that treatment with bedaquiline\u2013pretomanid\u2013linezolid is efficacious and well tolerated in only 6 months, a breakthrough compared with previous TB therapies.","journal-title":"N. Engl. J. Med."},{"key":"933_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/ng.2517","volume":"45","author":"P Supply","year":"2013","unstructured":"Supply, P. et al. Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Nat. Genet. 45, 172\u2013179 (2013).","journal-title":"Nat. Genet."},{"key":"933_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2724-z","volume":"18","author":"EG Tse","year":"2019","unstructured":"Tse, E. G., Korsik, M. & Todd, M. H. The past, present and future of anti-malarial medicines. Malar. J. 18, 93 (2019).","journal-title":"Malar. J."},{"key":"933_CR12","unstructured":"World Health Organization. WHO Guidelines for Malaria (WHO, 2021)."},{"key":"933_CR13","doi-asserted-by":"publisher","first-page":"9109","DOI":"10.1073\/pnas.85.23.9109","volume":"85","author":"AF Cowman","year":"1988","unstructured":"Cowman, A. F., Morry, M. J., Biggs, B. A., Cross, G. A. & Foote, S. J. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase\u2013thymidylate synthase gene of Plasmodium falciparum. Proc. Natl Acad. Sci. USA 85, 9109\u20139113 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR14","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1073\/pnas.87.8.3018","volume":"87","author":"DS Peterson","year":"1990","unstructured":"Peterson, D. S., Milhous, W. K. & Wellems, T. E. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl Acad. Sci. USA 87, 3018\u20133022 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0166-6851(92)90047-N","volume":"52","author":"S Thaithong","year":"1992","unstructured":"Thaithong, S. et al. Pyrimethamine resistant mutations in Plasmodium falciparum. Mol. Biochem. Parasitol. 52, 149\u2013157 (1992).","journal-title":"Mol. Biochem. Parasitol."},{"key":"933_CR16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1073\/pnas.94.4.1124","volume":"94","author":"W Sirawaraporn","year":"1997","unstructured":"Sirawaraporn, W., Sathitkul, T., Sirawaraporn, R., Yuthavong, Y. & Santi, D. V. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl Acad. Sci. USA 94, 1124\u20131129 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1432-1033.1994.00397.x","volume":"224","author":"DR Brooks","year":"1994","unstructured":"Brooks, D. R. et al. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem. 224, 397\u2013405 (1994).","journal-title":"Eur. J. Biochem."},{"key":"933_CR18","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.1073\/pnas.91.15.7149","volume":"91","author":"T Triglia","year":"1994","unstructured":"Triglia, T. & Cowman, A. F. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl Acad. Sci. USA 91, 7149\u20137153 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1086\/375599","volume":"37","author":"E Schwartz","year":"2003","unstructured":"Schwartz, E., Bujanover, S. & Kain, K. C. Genetic confirmation of atovaquone\u2013proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin. Infect. Dis. 37, 450\u2013451 (2003).","journal-title":"Clin. Infect. Dis."},{"key":"933_CR20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1086\/427782","volume":"191","author":"SR Meshnick","year":"2005","unstructured":"Meshnick, S. R., Trumpower, B., Wichmann, O. & Jelinek, T. Multiple cytochrome b mutations may cause atovaquone resistance. J. Infect. Dis. 191, 822\u2013823 (2005).","journal-title":"J. Infect. Dis."},{"key":"933_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM200101253440403","volume":"344","author":"A Djimd\u00e9","year":"2001","unstructured":"Djimd\u00e9, A. et al. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344, 257\u2013263 (2001). This pivotal study on drug resistance in malaria demonstrates that the pfcrt T76 mutation in P. falciparum is associated with clinical resistance to chloroquine, suggesting that this mutation can be used as a marker in surveillance for chloroquine-resistant P. falciparum malaria.","journal-title":"N. Engl. J. Med."},{"key":"933_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1126\/science.1074045","volume":"298","author":"ABS Sidhu","year":"2002","unstructured":"Sidhu, A. B. S., Verdier-Pinard, D. & Fidock, D. A. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298, 210\u2013213 (2002).","journal-title":"Science"},{"key":"933_CR23","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1038\/sj.emboj.7600681","volume":"24","author":"V Lakshmanan","year":"2005","unstructured":"Lakshmanan, V. et al. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 24, 2294\u20132305 (2005).","journal-title":"EMBO J."},{"key":"933_CR24","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/S1473-3099(19)30543-2","volume":"19","author":"SK Dhingra","year":"2019","unstructured":"Dhingra, S. K., Small-Saunders, J. L., M\u00e9nard, D. & Fidock, D. A. Plasmodium falciparum resistance to piperaquine driven by PfCRT. Lancet Infect. Dis. 19, 1168\u20131169 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"933_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-05652-0","volume":"9","author":"LS Ross","year":"2018","unstructured":"Ross, L. S. et al. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat. Commun. 9, 1\u201313 (2018).","journal-title":"Nat. Commun."},{"key":"933_CR26","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1128\/AAC.47.8.2418-2423.2003","volume":"47","author":"AL Pickard","year":"2003","unstructured":"Pickard, A. L. et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob. Agents Chemother. 47, 2418\u20132423 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"RN Price","year":"2004","unstructured":"Price, R. N. et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364, 438\u2013447 (2004).","journal-title":"Lancet"},{"key":"933_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","volume":"17","author":"B Witkowski","year":"2017","unstructured":"Witkowski, B. et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study. Lancet Infect. Dis. 17, 174\u2013183 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"933_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijpddr.2018.11.004","volume":"9","author":"D Loesbanluechai","year":"2019","unstructured":"Loesbanluechai, D. et al. Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine. Int. J. Parasitol. Drugs Drug. Resist. 9, 16\u201322 (2019).","journal-title":"Int. J. Parasitol. Drugs Drug. Resist."},{"key":"933_CR30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tips.2017.03.007","volume":"38","author":"J Wang","year":"2017","unstructured":"Wang, J., Xu, C., Lun, Z.-R. & Meshnick, S. R. Unpacking \u2018artemisinin resistance\u2019. Trends Pharmacol. Sci. 38, 506\u2013511 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"933_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2013","unstructured":"Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50\u201355 (2013). This work identifies the molecular marker of the partial artemisinin resistance threatening the long-term clinical efficacy of current front-line antimalarials.","journal-title":"Nature"},{"key":"933_CR32","unstructured":"World Health Organization. Report on Antimalarial drug Efficacy, Resistance and Response: 10\u2009years of Surveillance (2010\u20132019) (WHO, 2020)."},{"key":"933_CR33","first-page":"409","volume":"4","author":"AM Dondorp","year":"2016","unstructured":"Dondorp, A. M. & Fairhurst, R. M. Artemisinin-resistant Plasmodium falciparum Malaria. Microbiol. Spectrum 4, 409\u2013429 (2016).","journal-title":"Microbiol. Spectrum"},{"key":"933_CR34","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala, B. et al. Evidence of artemisinin-resistant malaria in Africa. N. Engl. J. Med. 385, 1163\u20131171 (2021).","journal-title":"N. Engl. J. Med."},{"key":"933_CR35","first-page":"1","volume":"1","author":"SG Deeks","year":"2015","unstructured":"Deeks, S. G., Overbaugh, J., Phillips, A. & Buchbinder, S. HIV infection. Nat. Rev. Dis. Prim. 1, 1\u201322 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"933_CR36","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1128\/jvi.69.8.5087-5094.1995","volume":"69","author":"LM Mansky","year":"1995","unstructured":"Mansky, L. M. & Temin, H. M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69, 5087\u20135094 (1995).","journal-title":"J. Virol."},{"key":"933_CR37","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.1128\/JVI.00915-10","volume":"84","author":"ME Abram","year":"2010","unstructured":"Abram, M. E., Ferris, A. L., Shao, W., Alvord, W. G. & Hughes, S. H. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J. Virol. 84, 9864\u20139878 (2010).","journal-title":"J. Virol."},{"key":"933_CR38","first-page":"195","volume":"4","author":"W An","year":"2022","unstructured":"An, W. & Telesnitsky, A. HIV-1 genetic recombination: experimental approaches and observations. AIDS Rev. 4, 195\u2013212 (2022).","journal-title":"AIDS Rev."},{"key":"933_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04217-5","volume":"9","author":"H Song","year":"2018","unstructured":"Song, H. et al. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat. Commun. 9, 1928 (2018).","journal-title":"Nat. Commun."},{"key":"933_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1126\/science.7824947","volume":"267","author":"JM Coffin","year":"1995","unstructured":"Coffin, J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483\u2013489 (1995).","journal-title":"Science"},{"key":"933_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-11-96","volume":"11","author":"AS Perelson","year":"2013","unstructured":"Perelson, A. S. & Ribeiro, R. M. Modeling the within-host dynamics of HIV infection. BMC Biol. 11, 96 (2013).","journal-title":"BMC Biol."},{"key":"933_CR42","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1128\/JVI.00495-16","volume":"90","author":"S-Y Rhee","year":"2016","unstructured":"Rhee, S.-Y. et al. HIV-1 protease, reverse transcriptase, and integrase variation. J. Virol. 90, 6058\u20136070 (2016).","journal-title":"J. Virol."},{"key":"933_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/jac\/dkz417","volume":"75","author":"PL Tzou","year":"2020","unstructured":"Tzou, P. L. et al. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. J. Antimicrob. Chemother. 75, 170\u2013182 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"933_CR44","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1128\/AAC.00566-11","volume":"55","author":"MD Marsden","year":"2011","unstructured":"Marsden, M. D., Avancena, P., Kitchen, C. M. R., Hubbard, T. & Zack, J. A. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob. Agents Chemother. 55, 3696\u20133702 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.69032","volume":"10","author":"AF Feder","year":"2021","unstructured":"Feder, A. F., Harper, K. N., Brumme, C. J. & Pennings, P. S. Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity. eLife 10, e69032 (2021). This work analyses the evolution of HIV drug resistance from a spatial-temporal perspective during long-term drug treatment.","journal-title":"eLife"},{"key":"933_CR46","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1128\/AAC.46.3.909-912.2002","volume":"46","author":"PR Harrigan","year":"2002","unstructured":"Harrigan, P. R. & Larder, B. A. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimicrob. Agents Chemother. 46, 909\u2013912 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR47","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/v13050735","volume":"13","author":"T Xiao","year":"2021","unstructured":"Xiao, T., Cai, Y. & Chen, B. HIV-1 entry and membrane fusion inhibitors. Viruses 13, 735 (2021).","journal-title":"Viruses"},{"key":"933_CR48","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","volume":"584","author":"JO Link","year":"2020","unstructured":"Link, J. O. et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584, 614\u2013618 (2020). This work supports the need for studying and modelling temporal and spatial aspects of anti-HIV drug exposure to help better understand and mitigate drug resistance.","journal-title":"Nature"},{"key":"933_CR49","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/v2020606","volume":"2","author":"K Singh","year":"2010","unstructured":"Singh, K., Marchand, B., Kirby, K. A., Michailidis, E. & Sarafianos, S. G. Structural aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruses 2, 606\u2013638 (2010).","journal-title":"Viruses"},{"key":"933_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.virusres.2007.12.015","volume":"134","author":"L Men\u00e9ndez-Arias","year":"2008","unstructured":"Men\u00e9ndez-Arias, L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. 134, 124\u2013146 (2008).","journal-title":"Virus Res."},{"key":"933_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-9-63","volume":"9","author":"A Fun","year":"2012","unstructured":"Fun, A., Wensing, A. M. J., Verheyen, J. & Nijhuis, M. Human immunodeficiency virus gag and protease: partners in resistance. Retrovirology 9, 63 (2012).","journal-title":"Retrovirology"},{"key":"933_CR52","unstructured":"World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach (WHO, 2021)."},{"key":"933_CR53","unstructured":"US Department of Health and Human Services. HIV clinical guidelines: adult and adolescent ARV. ClinicalIinfo.HIV.gov https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new (2024)."},{"key":"933_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi, R. T. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel. JAMA 329, 63\u201384 (2023).","journal-title":"JAMA"},{"key":"933_CR55","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jconrel.2015.08.018","volume":"219","author":"M Hu","year":"2015","unstructured":"Hu, M., Patel, S. K., Zhou, T. & Rohan, L. C. Drug transporters in tissues and cells relevant to sexual transmission of HIV: implications for drug delivery. J. Control. Rel. 219, 681\u2013696 (2015).","journal-title":"J. Control. Rel."},{"key":"933_CR56","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.5588\/ijtld.15.0389","volume":"19","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y. & Yew, W. W. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int. J. Tuberculosis Lung Dis. 19, 1276\u20131289 (2015).","journal-title":"Int. J. Tuberculosis Lung Dis."},{"key":"933_CR57","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/femsre\/fux011","volume":"41","author":"SM Gygli","year":"2017","unstructured":"Gygli, S. M., Borrell, S., Trauner, A. & Gagneux, S. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol. Rev. 41, 354\u2013373 (2017).","journal-title":"FEMS Microbiol. Rev."},{"key":"933_CR58","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1574-6968.1996.tb08515.x","volume":"144","author":"H Taniguchi","year":"1996","unstructured":"Taniguchi, H. et al. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol. Lett. 144, 103\u2013108 (1996).","journal-title":"FEMS Microbiol. Lett."},{"key":"933_CR59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.8284673","volume":"263","author":"A Banerjee","year":"1994","unstructured":"Banerjee, A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227\u2013230 (1994).","journal-title":"Science"},{"key":"933_CR60","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1128\/AAC.41.8.1677","volume":"41","author":"S Sreevatsan","year":"1997","unstructured":"Sreevatsan, S. et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob. Agents Chemother. 41, 1677\u20131681 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2958.1995.tb02238.x","volume":"15","author":"B Heym","year":"1995","unstructured":"Heym, B., Alzari, P. M., Honore, N. & Cole, S. T. Missense mutations in the catalase\u2010peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 15, 235\u2013245 (1995).","journal-title":"Mol. Microbiol."},{"key":"933_CR62","first-page":"461","volume":"95","author":"K Konno","year":"1967","unstructured":"Konno, K., Feldmann, F. M. & McDermott, W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95, 461\u2013469 (1967).","journal-title":"Am. Rev. Respir. Dis."},{"key":"933_CR63","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nm0696-662","volume":"2","author":"A Scorpio","year":"1996","unstructured":"Scorpio, A. & Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2, 662\u2013667 (1996).","journal-title":"Nat. Med."},{"key":"933_CR64","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1073\/pnas.0508392103","volume":"103","author":"UH Manjunatha","year":"2006","unstructured":"Manjunatha, U. H. et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 431\u2013436 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR65","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1128\/AAC.47.12.3799-3805.2003","volume":"47","author":"GP Morlock","year":"2003","unstructured":"Morlock, G. P., Metchock, B., Sikes, D., Crawford, J. T. & Cooksey, R. C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 47, 3799\u20133805 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR66","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1128\/AAC.00112-06","volume":"50","author":"MH Hazb\u00f3n","year":"2006","unstructured":"Hazb\u00f3n, M. H. et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50, 2640\u20132649 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR67","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1128\/AAC.00037-14","volume":"58","author":"RC Hartkoorn","year":"2014","unstructured":"Hartkoorn, R. C., Uplekar, S. & Cole, S. T. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 2979\u20132981 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR68","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1056\/NEJMc1505196","volume":"373","author":"GV Bloemberg","year":"2015","unstructured":"Bloemberg, G. V. et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N. Engl. J. Med. 373, 1986\u20131988 (2015).","journal-title":"N. Engl. J. Med."},{"key":"933_CR69","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jac\/dkt358","volume":"69","author":"H Nebenzahl-Guimaraes","year":"2014","unstructured":"Nebenzahl-Guimaraes, H., Jacobson, K. R., Farhat, M. R. & Murray, M. B. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 69, 331\u2013342 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"933_CR70","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/S2666-5247(21)00301-3","volume":"3","author":"TM Walker","year":"2022","unstructured":"Walker, T. M. et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe 3, e265\u2013e273 (2022).","journal-title":"Lancet Microbe"},{"key":"933_CR71","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/infdis\/jiaa625","volume":"225","author":"K Hjort","year":"2022","unstructured":"Hjort, K. et al. Dynamics of extensive drug resistance evolution of Mycobacterium tuberculosis in a single patient during 9\u2009years of disease and treatment. J. Infect. Dis. 225, 1011\u20131020 (2022).","journal-title":"J. Infect. Dis."},{"key":"933_CR72","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng.1038","volume":"44","author":"I Comas","year":"2011","unstructured":"Comas, I. et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44, 106\u2013110 (2011).","journal-title":"Nat. Genet."},{"key":"933_CR73","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","volume":"105","author":"MF Boni","year":"2008","unstructured":"Boni, M. F., Smith, D. L. & Laxminarayan, R. Benefits of using multiple first-line therapies against malaria. Proc. Natl Acad. Sci. USA 105, 14216\u201314221 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001984","volume":"13","author":"MF Boni","year":"2016","unstructured":"Boni, M. F., White, N. J. & Baird, J. K. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLoS Med 13, e1001984 (2016).","journal-title":"PLoS Med"},{"key":"933_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040220","volume":"11","author":"M Siribie","year":"2021","unstructured":"Siribie, M. et al. Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso. BMJ Open 11, e040220 (2021).","journal-title":"BMJ Open"},{"key":"933_CR76","first-page":"1","volume":"2","author":"M Pai","year":"2016","unstructured":"Pai, M. et al. Tuberculosis. Nat. Rev. Dis. Prim. 2, 1\u201323 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"933_CR77","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","volume":"393","author":"J Furin","year":"2019","unstructured":"Furin, J., Cox, H. & Pai, M. Tuberculosis. Lancet 393, 1642\u20131656 (2019).","journal-title":"Lancet"},{"key":"933_CR78","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pt.2020.09.011","volume":"37","author":"RW van der Pluijm","year":"2021","unstructured":"van der Pluijm, R. W., Amaratunga, C., Dhorda, M. & Dondorp, A. M. Triple artemisinin-based combination therapies for malaria\u2014a new paradigm? Trends Parasitol. 37, 15\u201324 (2021).","journal-title":"Trends Parasitol."},{"key":"933_CR79","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1473-3099(21)00692-7","volume":"22","author":"TJ Peto","year":"2022","unstructured":"Peto, T. J. et al. Triple therapy with artemether\u2013lumefantrine plus amodiaquine versus artemether\u2013lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect. Dis. 22, 867\u2013878 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"933_CR80","doi-asserted-by":"publisher","first-page":"876282","DOI":"10.3389\/fphar.2022.876282","volume":"13","author":"B Hanboonkunupakarn","year":"2022","unstructured":"Hanboonkunupakarn, B., Tarning, J., Pukrittayakamee, S. & Chotivanich, K. Artemisinin resistance and malaria elimination: where are we now? Front. Pharmacol. 13, 876282 (2022).","journal-title":"Front. Pharmacol."},{"key":"933_CR81","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrmicro2331","volume":"8","author":"AM Dondorp","year":"2010","unstructured":"Dondorp, A. M. et al. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 8, 272\u2013280 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"933_CR82","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","volume":"21","author":"JS McCarthy","year":"2021","unstructured":"McCarthy, J. S. et al. Safety, pharmacokinetics, and antimalarial activity of the novel Plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. Lancet Infect. Dis. 21, 1713\u20131724 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"933_CR83","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","volume":"18","author":"A Llanos-Cuentas","year":"2018","unstructured":"Llanos-Cuentas, A. et al. Antimalarial activity of single-dose DSM265, a novel Plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase. Lancet Infect. Dis. 18, 874\u2013883 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"933_CR84","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/cid\/ciab716","volume":"74","author":"EK Schmitt","year":"2021","unstructured":"Schmitt, E. K. et al. Efficacy of cipargamin (KAE609) in a randomized, phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria. Clin. Infect. Dis. 74, 1831\u20131839 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"933_CR85","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1126\/science.aar4189","volume":"359","author":"JM Carlton","year":"2018","unstructured":"Carlton, J. M. Malaria parasite evolution in a test tube. Science 359, 159\u2013160 (2018).","journal-title":"Science"},{"key":"933_CR86","doi-asserted-by":"publisher","first-page":"117863611880852","DOI":"10.1177\/1178636118808529","volume":"11","author":"A Cowell","year":"2018","unstructured":"Cowell, A. & Winzeler, E. Exploration of the Plasmodium falciparum resistome and druggable genome reveals new mechanisms of drug resistance and antimalarial targets. Microbiol. Insights 11, 117863611880852 (2018).","journal-title":"Microbiol. Insights"},{"key":"933_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11901","volume":"7","author":"VC Corey","year":"2016","unstructured":"Corey, V. C. et al. A broad analysis of resistance development in the malaria parasite. Nat. Commun. 7, 11901 (2016).","journal-title":"Nat. Commun."},{"key":"933_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154166","volume":"11","author":"AH Lee","year":"2016","unstructured":"Lee, A. H. & Fidock, D. A. Evidence of a mild mutator phenotype in Cambodian Plasmodium falciparum malaria parasites. PLoS ONE 11, e0154166 (2016).","journal-title":"PLoS ONE"},{"key":"933_CR89","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.pt.2021.04.006","volume":"37","author":"M Duffey","year":"2021","unstructured":"Duffey, M. et al. Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials. Trends Parasitol. 37, 709\u2013721 (2021). This work presents a landmark proposition for a strategy to deprioritize compounds in the discovery phase of anti-infectious drugs on the basis of the prediction of their propensity to generate resistance in the clinic.","journal-title":"Trends Parasitol."},{"key":"933_CR90","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.85023","volume":"12","author":"REK Mandt","year":"2023","unstructured":"Mandt, R. E. K. et al. Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance. eLife 12, e85023 (2023).","journal-title":"eLife"},{"key":"933_CR91","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","volume":"3","author":"S Kanters","year":"2016","unstructured":"Kanters, S. et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet Hiv. 3, e510\u2013e520 (2016).","journal-title":"Lancet Hiv."},{"key":"933_CR92","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bcp.12403","volume":"79","author":"A Tseng","year":"2015","unstructured":"Tseng, A., Seet, J. & Phillips, E. J. The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br. J. Clin. Pharmacol. 79, 182 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"933_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/aid.2019.0171","volume":"36","author":"M Boffito","year":"2020","unstructured":"Boffito, M. et al. Perspectives on the barrier to resistance for dolutegravir\u2009+\u2009lamivudine, a two-drug antiretroviral therapy for HIV-1 infection. AIDS Res. Hum. Retroviruses 36, 13\u201318 (2020).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"933_CR94","doi-asserted-by":"publisher","first-page":"e02104","DOI":"10.1128\/AAC.02104-18","volume":"63","author":"T Yoshinaga","year":"2019","unstructured":"Yoshinaga, T., Miki, S., Kawauchi-Miki, S., Seki, T. & Fujiwara, T. Barrier to resistance of dolutegravir in two-drug combinations. Antimicrob. Agents Chemother. 63, e02104\u2013e02118 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR95","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1021\/jm030558s","volume":"47","author":"K Das","year":"2004","unstructured":"Das, K. et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47, 2550\u20132560 (2004).","journal-title":"J. Med. Chem."},{"key":"933_CR96","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"P Cahn","year":"2019","unstructured":"Cahn, P. et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week\u200948 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 393, 143\u2013155 (2019). This work supports a new paradigm in drug combination by demonstrating the efficacy, non-inferiority and tolerability of a two-drug anti-HIV regimen over a three-drug regimen.","journal-title":"Lancet"},{"key":"933_CR97","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1086\/378281","volume":"188","author":"JM Whitcomb","year":"2003","unstructured":"Whitcomb, J. M., Parkin, N. T., Chappey, C., Hellmann, N. S. & Petropoulos, C. J. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J. Infect. Dis. 188, 992\u20131000 (2003).","journal-title":"J. Infect. Dis."},{"key":"933_CR98","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/tmi.12297","volume":"19","author":"R Ramjan","year":"2014","unstructured":"Ramjan, R. et al. Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. Trop. Med. Int. Health 19, 501\u2013513 (2014).","journal-title":"Trop. Med. Int. Health"},{"key":"933_CR99","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin, C. et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N. Engl. J. Med. 382, 1124\u20131135 (2020).","journal-title":"N. Engl. J. Med."},{"key":"933_CR100","first-page":"111","volume":"27","author":"AM Wensing","year":"2019","unstructured":"Wensing, A. M. et al. 2019 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 27, 111 (2019).","journal-title":"Top. Antivir. Med."},{"key":"933_CR101","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/infdis\/jiaa683","volume":"224","author":"S Bertagnolio","year":"2021","unstructured":"Bertagnolio, S. et al. Clinical impact of pretreatment human immunodeficiency virus drug resistance in people initiating nonnucleoside reverse transcriptase inhibitor\u2013containing antiretroviral therapy: a systematic review and meta-analysis. J. Infect. Dis. 224, 377\u2013388 (2021).","journal-title":"J. Infect. Dis."},{"key":"933_CR102","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/COH.0000000000000743","volume":"17","author":"S Bertagnolio","year":"2022","unstructured":"Bertagnolio, S., Jordan, M. R., Giron, A. & Inzaule, S. Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence. Curr. Opin. Hiv. AIDS 17, 229\u2013239 (2022).","journal-title":"Curr. Opin. Hiv. AIDS"},{"key":"933_CR103","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/hiv.13095","volume":"22","author":"J Fokam","year":"2021","unstructured":"Fokam, J. et al. Alarming rates of virological failure and HIV-1 drug resistance amongst adolescents living with perinatal HIV in both urban and rural settings: evidence from the EDCTP READY-study in Cameroon. Hiv. Med. 22, 567\u2013580 (2021).","journal-title":"Hiv. Med."},{"key":"933_CR104","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/QAI.0000000000002850","volume":"89","author":"W Nyandiko","year":"2022","unstructured":"Nyandiko, W. et al. HIV-1 treatment failure, drug resistance, and clinical outcomes in perinatally infected children and adolescents failing first-line antiretroviral therapy in western Kenya. J. Acquir. Immune Defic. Syndr. 89, 231\u2013239 (2022).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"933_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267159","volume":"17","author":"M Melku","year":"2022","unstructured":"Melku, M., Gesesew, H. A. & Ward, P. R. Magnitude and predictors of HIV-drug resistance in Africa: a protocol for systematic review and meta-analysis. PLoS ONE 17, e0267159 (2022).","journal-title":"PLoS ONE"},{"key":"933_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-019-2991-2","volume":"20","author":"E Ramon","year":"2019","unstructured":"Ramon, E., Belanche-Mu\u00f1oz, L. & P\u00e9rez-Enciso, M. HIV drug resistance prediction with weighted categorical kernel functions. BMC Bioinforma. 20, 1\u201313 (2019).","journal-title":"BMC Bioinforma."},{"key":"933_CR107","first-page":"56","volume":"17","author":"JM Llibre","year":"2015","unstructured":"Llibre, J. M. et al. Resistance profile and genetic barrier of dolutegravir. AIDS Rev. 17, 56\u201364 (2015).","journal-title":"AIDS Rev."},{"key":"933_CR108","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0166-3542(99)00010-8","volume":"42","author":"H R\u00fcbsamen-Waigmann","year":"1999","unstructured":"R\u00fcbsamen-Waigmann, H. et al. Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro. Antivir. Res. 42, 15\u201324 (1999).","journal-title":"Antivir. Res."},{"key":"933_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-017-0360-7","volume":"14","author":"K Anstett","year":"2017","unstructured":"Anstett, K., Brenner, B., Mesplede, T. & Wainberg, M. A. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology 14, 1\u201316 (2017).","journal-title":"Retrovirology"},{"key":"933_CR110","doi-asserted-by":"publisher","first-page":"9040","DOI":"10.1073\/pnas.1820333116","volume":"116","author":"R van Duyne","year":"2019","unstructured":"van Duyne, R., Kuo, L. S., Pham, P., Fujii, K. & Freed, E. O. Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle. Proc. Natl Acad. Sci. USA 116, 9040\u20139049 (2019). This work shows how compensatory mutations in the envelope glycoprotein gene of HIV can provide growth advantage to the virus by rescuing replication defective mutants, a finding that can explain the evolution of HIV drug resistance.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR111","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fphar.2015.00090","volume":"6","author":"MA Wainberg","year":"2015","unstructured":"Wainberg, M. A. & Han, Y. S. Will drug resistance against dolutegravir in initial therapy ever occur? Front. Pharmacol. 6, 90 (2015).","journal-title":"Front. Pharmacol."},{"key":"933_CR112","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3389\/fmicb.2015.00517","volume":"6","author":"J Zhu","year":"2015","unstructured":"Zhu, J., da, Meng, W., Wang, X. J. & Wang, H. C. R. Broad-spectrum antiviral agents. Front. Microbiol. 6, 517 (2015).","journal-title":"Front. Microbiol."},{"key":"933_CR113","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/chemistry4020019","volume":"4","author":"T K\u00e1lai","year":"2022","unstructured":"K\u00e1lai, T., Pongr\u00e1cz, J. E. & M\u00e1tyus, P. Recent advances in influenza, HIV and SARS-CoV-2 infection prevention and drug treatment\u2014the need for precision medicine. Chemistry 4, 216\u2013258 (2022).","journal-title":"Chemistry"},{"key":"933_CR114","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1021\/acsmedchemlett.2c00115","volume":"13","author":"K Parcella","year":"2022","unstructured":"Parcella, K. et al. Discovery and preclinical profiling of GSK3839919, a potent HIV-1 allosteric integrase inhibitor. ACS Med. Chem. Lett. 13, 972\u2013980 (2022).","journal-title":"ACS Med. Chem. Lett."},{"key":"933_CR115","doi-asserted-by":"publisher","first-page":"e01876","DOI":"10.1128\/AAC.01876-21","volume":"66","author":"I Dicker","year":"2022","unstructured":"Dicker, I. et al. GSK3640254 is a novel HIV-1 maturation inhibitor with an optimized virology profile. Antimicrob. Agents Chemother. 66, e01876\u2013e01921 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009671","volume":"17","author":"T Maehigashi","year":"2021","unstructured":"Maehigashi, T. et al. A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF\/p75-integrase interaction site. PLoS Pathog. 17, e1009671 (2021).","journal-title":"PLoS Pathog."},{"key":"933_CR117","doi-asserted-by":"publisher","first-page":"e01586","DOI":"10.1128\/mBio.01586-16","volume":"8","author":"CA Kerantzas","year":"2017","unstructured":"Kerantzas, C. A. & Jacobs, W. R. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. mBio 8, e01586\u2013e01616 (2017).","journal-title":"mBio"},{"key":"933_CR118","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","volume":"384","author":"SE Dorman","year":"2021","unstructured":"Dorman, S. E. et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N. Engl. J. Med. 384, 1705\u20131718 (2021). This work, in the landscape of very long and sometimes inefficient TB treatments, shows for the first time that a 4-month treatment is non-inferior to the standard 6-month treatment.","journal-title":"N. Engl. J. Med."},{"key":"933_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002595","volume":"15","author":"N Alipanah","year":"2018","unstructured":"Alipanah, N. et al. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med. 15, e1002595 (2018).","journal-title":"PLoS Med."},{"key":"933_CR120","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1128\/AAC.00308-15","volume":"59","author":"HL Haver","year":"2015","unstructured":"Haver, H. L. et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59, 5316\u20135323 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR121","first-page":"e01948","volume":"65","author":"D Rifat","year":"2021","unstructured":"Rifat, D. et al. Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 65, e01948\u2013e02020 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR122","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/jac\/dkab505","volume":"77","author":"SE Mudde","year":"2022","unstructured":"Mudde, S. E., Upton, A. M., Lenaerts, A., Bax, H. I. & de Steenwinkel, J. E. M. Delamanid or pretomanid? A Solomonic judgement! J. Antimicrob. Chemother. 77, 880\u2013902 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"933_CR123","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries, K. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223\u2013227 (2005).","journal-title":"Science"},{"key":"933_CR124","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","volume":"22","author":"NA Ismail","year":"2022","unstructured":"Ismail, N. A. et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect. Dis. 22, 496\u2013506 (2022). This work explains how an anti-TB drug used to treat patients infected with MDR Mtb can become inefficient because of novel resistance.","journal-title":"Lancet Infect. Dis."},{"key":"933_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002283","volume":"3","author":"J Timm Id","year":"2023","unstructured":"Timm Id, J. et al. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Glob. Public. Health 3, e0002283 (2023).","journal-title":"PLOS Glob. Public. Health"},{"key":"933_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0834-4","volume":"15","author":"AA Witney","year":"2017","unstructured":"Witney, A. A. et al. Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial. BMC Med 15, 71 (2017).","journal-title":"BMC Med"},{"key":"933_CR127","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3201\/eid2703.204418","volume":"27","author":"HZ Farooq","year":"2021","unstructured":"Farooq, H. Z. et al. Limited capability for testing Mycobacterium tuberculosis for susceptibility to new drugs. Emerg. Infect. Dis. 27, 985\u2013987 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"933_CR128","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001721","volume":"20","author":"DW Crook","year":"2022","unstructured":"Crook, D. W. et al. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. PLoS Biol. 20, e3001721 (2022).","journal-title":"PLoS Biol."},{"key":"933_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-021-00953-4","volume":"13","author":"MI Gr\u00f6schel","year":"2021","unstructured":"Gr\u00f6schel, M. I. et al. GenTB: a user-friendly genome-based predictor for tuberculosis resistance powered by machine learning. Genome Med. 13, 1\u201314 (2021).","journal-title":"Genome Med."},{"key":"933_CR130","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3389\/fgene.2019.00922","volume":"10","author":"W Deelder","year":"2019","unstructured":"Deelder, W. et al. Machine learning predicts accurately Mycobacterium tuberculosis drug resistance from whole genome sequencing data. Front. Genet. 10, 922 (2019).","journal-title":"Front. Genet."},{"key":"933_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-06449-4","volume":"12","author":"X Kuang","year":"2022","unstructured":"Kuang, X., Wang, F., Hernandez, K. M., Zhang, Z. & Grossman, R. L. Accurate and rapid prediction of tuberculosis drug resistance from genome sequence data using traditional machine learning algorithms and CNN. Sci. Rep. 12, 1\u201310 (2022). This work demonstrates the power of machine learning for a rapid and accurate prediction of TB drug resistance based on genomic data.","journal-title":"Sci. Rep."},{"key":"933_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000059","volume":"1","author":"S You","year":"2022","unstructured":"You, S. et al. Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods. PLOS Digital Health 1, e0000059 (2022).","journal-title":"PLOS Digital Health"},{"key":"933_CR133","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1126\/science.1124410","volume":"312","author":"S Gagneux","year":"2006","unstructured":"Gagneux, S. et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312, 1944\u20131946 (2006).","journal-title":"Science"},{"key":"933_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-37719-y","volume":"14","author":"C Loiseau","year":"2023","unstructured":"Loiseau, C. et al. The relative transmission fitness of multidrug-resistant Mycobacterium tuberculosis in a drug resistance hotspot. Nat. Commun. 14, 1\u201311 (2023). This work demonstrates that the transmission fitness of resistant TB strains can be as high as that of drug-sensitive pathogens.","journal-title":"Nat. Commun."},{"key":"933_CR135","doi-asserted-by":"publisher","first-page":"14711","DOI":"10.1073\/pnas.0902437106","volume":"106","author":"F Luciani","year":"2009","unstructured":"Luciani, F., Sisson, S. A., Jiang, H., Francis, A. R. & Tanaka, M. M. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 106, 14711\u201314715 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR136","doi-asserted-by":"publisher","first-page":"16823","DOI":"10.1073\/pnas.1204556109","volume":"109","author":"Y Yuthavong","year":"2012","unstructured":"Yuthavong, Y. et al. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc. Natl Acad. Sci. USA 109, 16823\u201316828 (2012). This work demonstrates the structure-based design of next-generation antimalarials that counteract successive rounds of parasite resistance mutations.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR137","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1016\/j.bmc.2016.07.039","volume":"24","author":"WL Jorgensen","year":"2016","unstructured":"Jorgensen, W. L. Computer-aided discovery of anti-HIV agents. Bioorg. Med. Chem. 24, 4768\u20134778 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"933_CR138","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.chembiol.2013.07.014","volume":"20","author":"MNL Nalam","year":"2013","unstructured":"Nalam, M. N. L. et al. Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem. Biol. 20, 1116\u20131124 (2013).","journal-title":"Chem. Biol."},{"key":"933_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-020-00516-2","volume":"17","author":"MD Marsden","year":"2020","unstructured":"Marsden, M. D. Benefits and limitations of humanized mice in HIV persistence studies. Retrovirology 17, 1\u20136 (2020).","journal-title":"Retrovirology"},{"key":"933_CR140","doi-asserted-by":"publisher","first-page":"12513","DOI":"10.1073\/pnas.1813386115","volume":"115","author":"JM S\u00e1","year":"2018","unstructured":"S\u00e1, J. M. et al. Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model. Proc. Natl Acad. Sci. USA 115, 12513\u201312518 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR141","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1126\/science.aan4472","volume":"359","author":"AN Cowell","year":"2018","unstructured":"Cowell, A. N. et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science 359, 191\u2013199 (2018).","journal-title":"Science"},{"key":"933_CR142","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.celrep.2016.06.026","volume":"16","author":"M D\u2019Antonio","year":"2016","unstructured":"D\u2019Antonio, M., Tamayo, P., Mesirov, J. P. & Frazer, K. A. Kataegis expression signature in breast cancer is associated with late onset, better prognosis, and higher HER2 levels. Cell Rep. 16, 672\u2013683 (2016).","journal-title":"Cell Rep."},{"key":"933_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0550-5","volume":"14","author":"WR Gimode","year":"2015","unstructured":"Gimode, W. R. et al. Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model. Malar. J. 14, 38 (2015).","journal-title":"Malar. J."},{"key":"933_CR144","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1021\/acsinfecdis.0c00724","volume":"7","author":"LB Arendse","year":"2021","unstructured":"Arendse, L. B., Wyllie, S., Chibale, K. & Gilbert, I. H. Plasmodium kinases as potential drug targets for malaria: challenges and opportunities. ACS Infect. Dis. 7, 518\u2013534 (2021).","journal-title":"ACS Infect. Dis."},{"key":"933_CR145","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","volume":"26","author":"D Paul","year":"2021","unstructured":"Paul, D. et al. Artificial intelligence in drug discovery and development. Drug. Discov. Today 26, 80\u201393 (2021).","journal-title":"Drug. Discov. Today"},{"key":"933_CR146","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1016\/j.cell.2021.06.033","volume":"184","author":"B Bosch","year":"2021","unstructured":"Bosch, B. et al. Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis. Cell 184, 4579\u20134592.e24 (2021).","journal-title":"Cell"},{"key":"933_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27516-4","volume":"13","author":"G Napier","year":"2023","unstructured":"Napier, G., Campino, S., Phelan, J. E. & Clark, T. G. Large-scale genomic analysis of Mycobacterium tuberculosis reveals extent of target and compensatory mutations linked to multi-drug resistant tuberculosis. Sci. Rep. 13, 623 (2023).","journal-title":"Sci. Rep."},{"key":"933_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-022-05422-4","volume":"15","author":"J Gill","year":"2022","unstructured":"Gill, J. & Sharma, A. Genomic analysis of single nucleotide polymorphisms in malaria parasite drug targets. Parasit. Vectors 15, 1\u201314 (2022).","journal-title":"Parasit. Vectors"},{"key":"933_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-37184-7","volume":"14","author":"NJE Waller","year":"2023","unstructured":"Waller, N. J. E., Cheung, C.-Y., Cook, G. M. & McNeil, M. B. The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis. Nat. Commun. 14, 1\u201315 (2023).","journal-title":"Nat. Commun."},{"key":"933_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-023-36921-2","volume":"14","author":"S Bopp","year":"2023","unstructured":"Bopp, S. et al. Potent acyl-CoA synthetase 10 inhibitors kill Plasmodium falciparum by disrupting triglyceride formation. Nat. Commun. 14, 1\u201315 (2023).","journal-title":"Nat. Commun."},{"key":"933_CR151","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1073\/pnas.1320886110","volume":"111","author":"AK Lukens","year":"2014","unstructured":"Lukens, A. K. et al. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance. Proc. Natl Acad. Sci. USA 111, 799\u2013804 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"933_CR152","doi-asserted-by":"publisher","first-page":"204ra132","DOI":"10.1126\/scitranslmed.3006609","volume":"5","author":"L Imamovic","year":"2013","unstructured":"Imamovic, L. & Sommer, M. O. A. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci. Transl. Med. 5, 204ra132 (2013).","journal-title":"Sci. Transl. Med."},{"key":"933_CR153","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","volume":"395","author":"RW van der Pluijm","year":"2020","unstructured":"van der Pluijm, R. W. et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet 395, 1345 (2020).","journal-title":"Lancet"},{"key":"933_CR154","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455\u2013467 (2009). This work presents the first report of partial resistance to artemisinin, a key component of the current front-line antimalarial combination therapies saving millions of lives.","journal-title":"N. Engl. J. Med."},{"key":"933_CR155","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/infdis\/jit077","volume":"207","author":"P Sawa","year":"2013","unstructured":"Sawa, P. et al. Malaria transmission after artemether\u2013lumefantrine and dihydroartemisinin\u2013piperaquine: a randomized trial. J. Infect. Dis. 207, 1637\u20131645 (2013).","journal-title":"J. Infect. Dis."},{"key":"933_CR156","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/infdis\/jiaa498","volume":"225","author":"K Stepniewska","year":"2022","unstructured":"Stepniewska, K. et al. Efficacy of single-dose primaquine with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission: an individual patient meta-analysis. J. Infect. Dis. 225, 1215\u20131226 (2022).","journal-title":"J. Infect. Dis."},{"key":"933_CR157","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","volume":"20","author":"VA Dartois","year":"2022","unstructured":"Dartois, V. A. & Rubin, E. J. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat. Rev. Microbiol. 20, 685\u2013701 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"933_CR158","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1016\/S2666-5247(22)00155-0","volume":"3","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Pre-existing partner-drug resistance to artemisinin combination therapies facilitates the emergence and spread of artemisinin resistance: a consensus modelling study. Lancet Microbe 3, e701\u2013e710 (2022).","journal-title":"Lancet Microbe"},{"key":"933_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-022-07067-1","volume":"22","author":"M Karmakar","year":"2022","unstructured":"Karmakar, M., Ragonnet, R., Ascher, D. B., Trauer, J. M. & Denholm, J. T. Estimating tuberculosis drug resistance amplification rates in high-burden settings. BMC Infect. Dis. 22, 1\u201312 (2022).","journal-title":"BMC Infect. Dis."},{"key":"933_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21187-3","volume":"12","author":"M Pascucci","year":"2021","unstructured":"Pascucci, M. et al. AI-based mobile application to fight antibiotic resistance. Nat. Commun. 12, 1\u201310 (2021).","journal-title":"Nat. Commun."},{"key":"933_CR161","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.3390\/electronics11172634","volume":"11","author":"M Singh","year":"2022","unstructured":"Singh, M. et al. Evolution of machine learning in tuberculosis diagnosis: a review of deep learning-based medical applications. Electronics 11, 2634 (2022).","journal-title":"Electronics"},{"key":"933_CR162","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","volume":"10","author":"JB Nachega","year":"2023","unstructured":"Nachega, J. B. et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV 10, e332\u2013e342 (2023).","journal-title":"Lancet HIV"},{"key":"933_CR163","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2021","unstructured":"Overton, E. T. et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 396, 1994\u20132005 (2021).","journal-title":"Lancet"},{"key":"933_CR164","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer, S. et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N. Engl. J. Med. 386, 1793\u20131803 (2022). This work demonstrates clinical efficacy for a capsid inhibitor in patients infected with MDR HIV-1.","journal-title":"N. Engl. J. Med."},{"key":"933_CR165","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/COH.0000000000000591","volume":"15","author":"ED Weld","year":"2020","unstructured":"Weld, E. D. & Flexner, C. Long-acting implants to treat and prevent HIV infection. Curr. Opin. Hiv. AIDS 15, 33\u201341 (2020).","journal-title":"Curr. Opin. Hiv. AIDS"},{"key":"933_CR166","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe, S. et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399, 1779\u20131789 (2022).","journal-title":"Lancet"},{"key":"933_CR167","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595\u2013608 (2021).","journal-title":"N. Engl. J. Med."},{"key":"933_CR168","unstructured":"Eron, J. J. et al. Lenacapavir with bNAbs GS-5423 and GS-2872 dosed every 6 months in people with HIV. In Conf. Retroviruses and Opportunistic Infections 193 (Univ. North Carolina at Chapel Hill, 2023)."},{"key":"933_CR169","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/COH.0000000000000735","volume":"17","author":"C Flexner","year":"2022","unstructured":"Flexner, C. The future of long-acting agents for preexposure prophylaxis. Curr. Opin. Hiv. AIDS 17, 192\u2013198 (2022).","journal-title":"Curr. Opin. Hiv. AIDS"},{"key":"933_CR170","first-page":"1","volume":"13","author":"M Kim","year":"2022","unstructured":"Kim, M. et al. A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis. Nat. Commun. 13, 1\u201316 (2022).","journal-title":"Nat. Commun."},{"key":"933_CR171","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","volume":"27","author":"SG Deeks","year":"2021","unstructured":"Deeks, S. G. et al. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat. Med. 27, 2085\u20132098 (2021).","journal-title":"Nat. Med."},{"key":"933_CR172","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2203067","volume":"387","author":"RL Wu","year":"2022","unstructured":"Wu, R. L. et al. Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria. N. Engl. J. Med. 387, 397\u2013407 (2022).","journal-title":"N. Engl. J. Med."},{"key":"933_CR173","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.3389\/fimmu.2021.816515","volume":"12","author":"H Mohamed","year":"2022","unstructured":"Mohamed, H. et al. Targeting CCR5 as a component of an HIV-1 therapeutic strategy. Front. Immunol. 12, 5686 (2022).","journal-title":"Front. Immunol."},{"key":"933_CR174","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/cid\/ciab160","volume":"73","author":"LSM Huang","year":"2021","unstructured":"Huang, L. S. M., Snyder, E. Y. & Schooley, R. T. Strategies and progress in CXCR4-targeted anti-human immunodeficiency virus (HIV) therapeutic development. Clin. Infect. Dis. 73, 919\u2013924 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"933_CR175","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005480","volume":"11","author":"S Lamotte","year":"2017","unstructured":"Lamotte, S., Sp\u00e4th, G. F., Rachidi, N. & Prina, E. The enemy within: targeting host\u2013parasite interaction for antileishmanial drug discovery. PLoS Negl. Trop. Dis. 11, e0005480 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"933_CR176","doi-asserted-by":"publisher","first-page":"100423","DOI":"10.1016\/j.xcrm.2021.100423","volume":"2","author":"L Wei","year":"2021","unstructured":"Wei, L. et al. Host-directed therapy, an untapped opportunity for antimalarial intervention. Cell Rep. Med. 2, 100423 (2021).","journal-title":"Cell Rep. Med."},{"key":"933_CR177","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","volume":"13","author":"C Young","year":"2020","unstructured":"Young, C., Walzl, G. & Du Plessis, N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 13, 190\u2013204 (2020).","journal-title":"Mucosal Immunol."},{"key":"933_CR178","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imr.12951","volume":"301","author":"G Kilin\u00e7","year":"2021","unstructured":"Kilin\u00e7, G., Saris, A., Ottenhoff, T. H. M. & Haks, M. C. Host-directed therapy to combat mycobacterial infections. Immunol. Rev. 301, 62\u201383 (2021).","journal-title":"Immunol. Rev."},{"key":"933_CR179","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210724","volume":"218","author":"HD Chien","year":"2021","unstructured":"Chien, H. D. et al. Imatinib augments standard malaria combination therapy without added toxicity. J. Exp. Med. 218, e20210724 (2021).","journal-title":"J. Exp. Med."},{"key":"933_CR180","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1128\/AAC.01584-21","volume":"66","author":"MF Chughlay","year":"2022","unstructured":"Chughlay, M. F. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of coadministered ruxolitinib and artemether\u2013lumefantrine in healthy adults. Antimicrob. Agents Chemother. 66, 1584\u20131605 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR181","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","volume":"61","author":"NA Meanwell","year":"2018","unstructured":"Meanwell, N. A. et al. Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir. J. Med. Chem. 61, 62\u201380 (2018).","journal-title":"J. Med. Chem."},{"key":"933_CR182","first-page":"S560","volume":"56","author":"M Sulkowski","year":"2012","unstructured":"Sulkowski, M. et al. Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B Inhibitor), +\/\u2212\u2009ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. J. Hepatol. 56, S560 (2012).","journal-title":"J. Hepatol."},{"key":"933_CR183","doi-asserted-by":"publisher","first-page":"886","DOI":"10.5588\/ijtld.21.0515","volume":"25","author":"MJ Boeree","year":"2021","unstructured":"Boeree, M. J. et al. UNITE4TB: a new consortium for clinical drug and regimen development for TB. Int. J. Tuberc. Lung Dis. 25, 886\u2013889 (2021).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"933_CR184","unstructured":"World Health Organization. WHO Guidelines for Malaria 2022 (WHO, 2022)."},{"key":"933_CR185","unstructured":"World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection (WHO, 2016)."},{"key":"933_CR186","unstructured":"World Health Organization. Rapid Communication: Key Changes to the Treatment of Drug-Resistant Tuberculosis (WHO, 2022)."},{"key":"933_CR187","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S0140-6736(22)01881-5","volume":"401","author":"M Saito","year":"2022","unstructured":"Saito, M. et al. Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis. Lancet 401, 118\u2013130 (2022).","journal-title":"Lancet"},{"key":"933_CR188","doi-asserted-by":"publisher","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","volume":"71","author":"W Carr","year":"2022","unstructured":"Carr, W. et al. Interim guidance: 4-month rifapentine\u2013moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis\u2014United States, 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 285\u2013289 (2022).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"933_CR189","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nrmicro1529","volume":"4","author":"M Prud\u00eancio","year":"2006","unstructured":"Prud\u00eancio, M., Rodriguez, A. & Mota, M. M. The silent path to thousands of merozoites: the Plasmodium liver stage. Nat. Rev. Microbiol. 4, 849\u2013856 (2006).","journal-title":"Nat. Rev. Microbiol."},{"key":"933_CR190","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","volume":"27","author":"B Chen","year":"2019","unstructured":"Chen, B. Molecular mechanism of HIV-1 entry. Trends Microbiol. 27, 878\u2013891 (2019).","journal-title":"Trends Microbiol."},{"key":"933_CR191","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41564-020-0735-8","volume":"5","author":"A Dharan","year":"2020","unstructured":"Dharan, A., Bachmann, N., Talley, S., Zwikelmaier, V. & Campbell, E. M. Nuclear pore blockade reveals that HIV-1 completes reverse transcription and uncoating in the nucleus. Nat. Microbiol. 5, 1088\u20131095 (2020).","journal-title":"Nat. Microbiol."},{"key":"933_CR192","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.cell.2021.01.025","volume":"184","author":"V Zila","year":"2021","unstructured":"Zila, V. et al. Cone-shaped HIV-1 capsids are transported through intact nuclear pores. Cell 184, 1032\u20131046.e18 (2021).","journal-title":"Cell"},{"key":"933_CR193","doi-asserted-by":"publisher","first-page":"a006924","DOI":"10.1101\/cshperspect.a006924","volume":"2","author":"WI Sundquist","year":"2012","unstructured":"Sundquist, W. I. & Kr\u00e4usslich, H. G. HIV-1 assembly, budding, and maturation. Cold Spring Harb. Perspect. Med. 2, a006924 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"933_CR194","unstructured":"United Nations Joint Program on HIV\/AIDS (UNAIDS). 90\u201390\u201390: An Ambitious Treatment Target to Help End the AIDS Epidemic 1\u201340 (UNAIDS, 2014)."},{"key":"933_CR195","unstructured":"World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021 Vol. 53 1689\u20131699 (WHO, 2021)."},{"key":"933_CR196","unstructured":"United Nations Joint Program on HIV\/AIDS (UNAIDS). 2021 UNAIDS Global AIDS Update\u2014Confronting Inequalities\u2014Lessons for Pandemic Responses from 40\u2009Years of AIDS 1\u2013386 (UNAIDS, 2021)."},{"key":"933_CR197","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1016\/S2352-3018(18)30094-8","volume":"5","author":"GS Gottlieb","year":"2018","unstructured":"Gottlieb, G. S., Raugi, D. N. & Smith, R. A. 90\u201390\u201390 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV 5, e390\u2013e399 (2018).","journal-title":"Lancet HIV"},{"key":"933_CR198","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RMGJ Houben","year":"2016","unstructured":"Houben, R. M. G. J. & Dodd, P. J. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 13, e1002152 (2016).","journal-title":"PLoS Med."},{"key":"933_CR199","unstructured":"World Health Organization. Global Tuberculosis Report (WHO, 2021)."},{"key":"933_CR200","unstructured":"World Health Organization. Global Tuberculosis Report 2020 (WHO, 2020)."},{"key":"933_CR201","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.300.4.423","volume":"300","author":"DV Havlir","year":"2008","unstructured":"Havlir, D. V., Getahun, H., Sanne, I. & Nunn, P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 300, 423\u2013430 (2008).","journal-title":"JAMA"},{"key":"933_CR202","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/S0140-6736(10)60483-7","volume":"375","author":"K L\u00f6nnroth","year":"2010","unstructured":"L\u00f6nnroth, K. et al. Tuberculosis control and elimination 2010\u201350: cure, care, and social development. Lancet 375, 1814\u20131829 (2010).","journal-title":"Lancet"},{"key":"933_CR203","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.puhe.2020.07.031","volume":"187","author":"N Obore","year":"2020","unstructured":"Obore, N., Kawuki, J., Guan, J., Papabathini, S. S. & Wang, L. Association between indoor air pollution, tobacco smoke and tuberculosis: an updated systematic review and meta-analysis. Public. Health 187, 24\u201335 (2020).","journal-title":"Public. Health"},{"key":"933_CR204","first-page":"1091","volume":"5","author":"CY Jeon","year":"2008","unstructured":"Jeon, C. Y. & Murray, M. B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 5, 1091\u20131101 (2008).","journal-title":"PLoS Med."},{"key":"933_CR205","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/archinte.167.4.335","volume":"167","author":"MN Bates","year":"2007","unstructured":"Bates, M. N. et al. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch. Intern. Med. 167, 335\u2013342 (2007).","journal-title":"Arch. Intern. Med."},{"key":"933_CR206","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239333","volume":"15","author":"A Burusie","year":"2020","unstructured":"Burusie, A., Enquesilassie, F., Addissie, A., Dessalegn, B. & Lamaro, T. Effect of smoking on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS ONE 15, e0239333 (2020).","journal-title":"PLoS ONE"},{"key":"933_CR207","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1111\/febs.14127","volume":"284","author":"AM Thu","year":"2017","unstructured":"Thu, A. M., Phyo, A. P., Landier, J., Parker, D. M. & Nosten, F. H. Combating multidrug-resistant Plasmodium falciparum malaria. FEBS J. 284, 2569\u20132578 (2017).","journal-title":"FEBS J."},{"key":"933_CR208","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nm.4381","volume":"23","author":"B Blasco","year":"2017","unstructured":"Blasco, B., Leroy, D. & Fidock, D. A. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat. Med. 23, 917\u2013928 (2017).","journal-title":"Nat. Med."},{"key":"933_CR209","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm, R. W. et al. Determinants of dihydroartemisinin\u2013piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect. Dis. 19, 952\u2013961 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"933_CR210","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1128\/AAC.00835-15","volume":"59","author":"R Leang","year":"2015","unstructured":"Leang, R. et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin\u2013piperaquine open-label multicenter clinical assessment. Antimicrob. Agents Chemother. 59, 4719\u20134726 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"933_CR211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-33873-x","volume":"13","author":"PK Tumwebaze","year":"2022","unstructured":"Tumwebaze, P. K. et al. Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nat. Commun. 13, 1\u201312 (2022).","journal-title":"Nat. Commun."},{"key":"933_CR212","unstructured":"World Health Organization. HIV Drug Resistance Report 2019 (WHO, 2019)."},{"key":"933_CR213","unstructured":"World Health Organization. Global Action Plan on HIV Drug Resistance 2017\u20132021: 2018 Progress Report\u2014HIV Drug Resistance 14 (WHO, 2018)."},{"key":"933_CR214","unstructured":"World Health Organization. HIV Drug Resistance Report 2021 138 (WHO, 2021)."},{"key":"933_CR215","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jac\/dkw463","volume":"72","author":"RS Boerma","year":"2017","unstructured":"Boerma, R. S. et al. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis. J. Antimicrob. Chemother. 72, 365\u2013371 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"933_CR216","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1097\/QAD.0000000000000494","volume":"28","author":"QD Pham","year":"2014","unstructured":"Pham, Q. D., Wilson, D. P., Law, M. G., Kelleher, A. D. & Zhang, L. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS 28, 2751\u20132762 (2014).","journal-title":"AIDS"},{"key":"933_CR217","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S2666-5247(20)30006-9","volume":"1","author":"MC Puertas","year":"2020","unstructured":"Puertas, M. C. et al. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. Artic. Lancet Microbe 1, 130\u2013165 (2020).","journal-title":"Artic. Lancet Microbe"},{"key":"933_CR218","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","volume":"16","author":"J Gregson","year":"2016","unstructured":"Gregson, J. et al. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect. Dis. 16, 565\u2013575 (2016).","journal-title":"Lancet Infect. Dis."},{"key":"933_CR219","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/cid\/ciab583","volume":"74","author":"RP McClung","year":"2022","unstructured":"McClung, R. P. et al. Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018. Clin. Infect. Dis. 74, 1055\u20131062 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"933_CR220","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","volume":"9","author":"RK Gupta","year":"2009","unstructured":"Gupta, R. K. et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect. Dis. 9, 409\u2013417 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"933_CR221","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25611","volume":"23","author":"SY Rhee","year":"2020","unstructured":"Rhee, S. Y. et al. HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates. J. Int. AIDS Soc. 23, e25611 (2020).","journal-title":"J. Int. AIDS Soc."},{"key":"933_CR222","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(12)60085-3","volume":"379","author":"S Loewenberg","year":"2012","unstructured":"Loewenberg, S. India reports cases of totally drug-resistant tuberculosis. Lancet 379, 205 (2012).","journal-title":"Lancet"},{"key":"933_CR223","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1378\/chest.08-2427","volume":"136","author":"AA Velayati","year":"2009","unstructured":"Velayati, A. A. et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136, 420\u2013425 (2009).","journal-title":"Chest"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-00933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-00933-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-00933-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T09:12:34Z","timestamp":1717578754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-024-00933-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":223,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1038\/s41573-024-00933-4","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"15 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D. is an employee of the Global Antibiotic Research & Development Partnership (GARDP, Geneva) and was an employee of MMV when this Review was drafted. R.W.S. is professor of medicine at Stanford University. D.L. and J.N.B. are working for Medicines for Malaria Venture (MMV, Geneva). J.T. and N.F. are working for TB Alliance. M.C. is currently CEO & President of the company Alphina Therapeutics\u00a0and consultant\/adviser for Exavir Therapeutics. He is\u00a0a former employee of ViiV Healthcare and a shareholder in GSK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}